The United Kingdom’s Food Standards Agency board has backed recommendations to authorize three high-purity CBD products as novel foods, advancing what would become the first CBD novel food authorizations in Great Britain.
The Food Standards Agency (FSA) board agreed Wednesday that recommendations covering all three applications are suitable to be presented to ministers in England and Wales, who will make the final authorization decisions.
The applications are RP 7, a synthetic CBD product submitted by Chanelle McCoy CBD Ltd.; RP 350, a CBD isolate from Cannaray Brands Ltd.; and RP 427, a hemp-derived CBD isolate submitted by EIHA Projects GmbH.
All three products contain CBD at a purity of at least 98% and were found to be safe under their proposed conditions of use following assessments involving the Advisory Committee on Novel Foods and Processes. The proposed authorizations would limit use to adults at a maximum daily intake of 10 milligrams of CBD.
The recommendations also include mandatory safety information warning against consumption by people under 18, those who are pregnant, breastfeeding or trying to conceive, and people taking medication or who are immunosuppressed. Products would also be required to comply with strict specifications limiting delta-9 THC and other controlled cannabinoids.
RP 7 and RP 427 would be authorized for use in food supplements, while Cannaray’s RP 350 application would also cover certain beverages and confectionery products in addition to supplements.
The FSA said approximately 3,000 individual CBD products currently appearing on its interim CBD Public List are linked to the three applications, meaning eventual ministerial authorization could represent a significant shift toward bringing a large portion of Britain’s existing CBD market into full regulatory compliance.
CBD foods are considered novel foods in Great Britain because they do not have a demonstrated history of significant food consumption before May 1997. Products therefore generally require authorization following a safety assessment before they can legally be placed on the market.
The FSA conducted a 12-week public consultation on the three applications beginning in August 2025. Of 46 responses received from consumers, businesses, trade groups and local authorities, 68% supported the agency’s proposed risk-management approach.
The board’s approval does not itself provide final market authorization. FSA officials will now finalize their recommendations and submit them to ministers in England and Wales, who will decide whether to formally authorize the products and the conditions attached to them.
If ministers approve the recommendations, the three products would become the first CBD novel foods authorized under Great Britain’s regulatory system. The FSA has already published positive safety assessments for additional high-purity CBD applications, potentially paving the way for further authorizations.
